

NWT Clinical Practice Information Notice

UPON RECEIPT: (1) PLEASE FOLLOW THE DIRECTIONS BELOW
 (2) FILE THIS NOTICE IN YOUR CLINICAL PRACTICE INFORMATION BINDER FOR FUTURE REFERENCE

The following clinical practice has been approved for use in the Northwest Territories Health and Social Services system, and has been distributed to:

Hospitals
 Community Health Centers
 Public Health Units
 Doctors' Offices
 Social Services Offices
 Other: _____

The information contained in this document is a Departmental:

Policy
 Standard
 Protocol
 Procedure
 Guidelines

Title: Meningococcal (Groups A, C, Y and W-135) Conjugate Program for Travelers

Effective Date: September 01, 2007

Statement of approved clinical practice: The National Advisory Committee and NWT Advisory Committee on Immunization recommends that all travelers requiring a broad coverage meningococcal vaccine receive one dose of Meningococcal Group A, C, Y and W-135 Vaccine.

- The NWT is using Menactra Vaccine for this program. It is to be given in a one-dose schedule of 0.5 ml intramuscularly.
- A randomized controlled trial of this vaccine demonstrated safety and immunogenicity for participants 11 to 55 years of age. However, it may be offered to 2 to 10 year olds and those over 55 years of age. Please see attachments for additional information.

Attachments: NWT Immunization Competency Exams to nurse managers.

Menactra Information Kit.

Reference: NACI Statement on the Recommended Use of Meningococcal Group A, C, Y, & W-135. CCDR 2007; Vol 33: ACS-3.

This clinical practice is approved. _____
 (signature)

Assistant Deputy Minister
 Chief Medical Officer of Health
 Director, Child & Family Services
 Director, Adoptions